Previous 10 | Next 10 |
CAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it has been selected for addition to the NASDAQ Bio...
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray, Ph.D., chief executive officer and ...
-Phase 1 INNATE trial will evaluate JTX-8064 as a monotherapy and in combination with Jounce’s PD-1 inhibitor, JTX-4014 - - O n track to begin enrollment by year-end 2020 - CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Jounc...
- Preclinical data highlight Jounce’s approach to identif y potential predictive and pharmacodynamic biomarkers to identify patients who may benefit from JTX-8064 - - Enrollment in Phase 1 monotherapy and PD-1 inhibitor combination ...
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a fireside ch...
Jounce Therapeutics, Inc. (JNCE) Q3 2020 Earnings Conference Call November 6, 2020 08:00 ET Company Participants Malin Deon - Investor Relations Rich Murray - Chief Executive Officer and President Elizabeth Trehu - Chief Medical Officer Kim Drapkin - Chief Financial Officer Conference Call Pa...
Image source: The Motley Fool. Jounce Therapeutics, Inc. (NASDAQ: JNCE) Q3 2020 Earnings Call Nov 6, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: Jounce Therapeutics, Inc. (JNCE) Q3 2020 Earnings Call Transcript ...
Jounce Therapeutics (JNCE): Q3 GAAP EPS of -$0.73 misses by $0.28.Cash, cash equivalents and investments of $105.3MPress Release For further details see: Jounce Therapeutics EPS misses by $0.28
-On track to begin enrollment in the Phase 1 trial for JTX-8064 by year-end 2020- -Established exclusive license agreement with Gilead for JTX-1811- -Initiated the Phase 2 SELECT biomarker selection trial of vopratelimab in combination with JTX-4014- -Company to ...
Gainers: Endurance International (EIGI) +61%.Superior Industries International (SUP) +35%.DBV Technologies (DBVT) +32%.Renren (RENN) +22%.Digital Ally (DGLY) +21%.Dunxin Financial (DXF) +19%.Par Pacific Holdings (PARR) +18%.Tricida (TCDA) +18%.Lumber Liquidators (LL) +17%.Vislink Technol...
News, Short Squeeze, Breakout and More Instantly...
Jounce Therapeutics Inc. Company Name:
JNCE Stock Symbol:
NASDAQ Market:
Jounce Therapeutics Inc. Website:
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Co...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or t...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE)...